.png){kind=small}
.png){kind=small}
BackTable / Tumor Board / Podcast / Episode #11
Immunotherapy & TACE in HCC Treatment
with Dr. Julius Chapiro and Dr. Richard Finn
There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.
This podcast is supported by an educational grant from Guerbet.
BackTable, LLC (Producer). (2025, April 29). Ep. 11 – Immunotherapy & TACE in HCC Treatment [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
The doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.
Timestamps
00:00 - Introduction
03:35 - HCC from an Oncologic Perspective
05:33 - Radiological Perspective on Liver Cancer
06:50 - Referral Patterns and Organizing a Multidisciplinary Approach
18:01 - Explaining TACE and Variations in the Procedure
27:27 - Choosing the Right Procedure for HCC
36:13 - Making a Decision on Medical Treatment Candidacy
42:23 - Importance of Data Driven HCC Treatment, Practical Insights, and Studies to Know
55:30 - Planning an Approach for a TACE Procedure
01:02:26 - Final Thoughts and Future Prospects in Liver Cancer Treatment
Resources
Barcelona Staging System:
https://www.ncbi.nlm.nih.gov/books/NBK569796/table/Ch3-t0001/
TRACE Trial:
https://pubs.rsna.org/doi/full/10.1148/radiol.211806
PREMIERE Trial:
https://www.gastrojournal.org/article/S0016-5085(16)34971-X/fulltext
EMERALD-1 Trial:
https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA432
LEAP O12 Study:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract
Transcript Preview
[Dr. Julius Chapiro]
I'm just very excited to be in a field that is so rapidly evolving and has brought a lot of change into the specialty...I think it's for the first time that this kind of disease that we treat also encounters a lot of interest from industry, from pharmaceutical industry. That means that there's a lot of advocacy. A lot of money just, frankly, coming into the specialty. I think that's an opportunity for us to ask the right questions, do the right trials, get them funded and get them done. I think that's a once-in-a-lifetime opportunity where, if we don't lead, we're going to be followers. I think that it's going to be up to us to generate the high-level data that we need to maintain our membership in the multidisciplinary care team.
The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
Articles
The HCC Clinical Trials That Every Interventional Radiologist Should Know
TACE & Immunotherapy for HCC: Treatment Selection & Timing
Topics
